生物帮生物通

采购帮忙热线
020-87540820
020-38498013
 
当前位置: 首页 » 行业资讯 » 行业资讯 » 正文

Intrexon收购克迪科思(Codexis)的实验室业务,向欧洲扩张

放大字体  缩小字体 发布日期:2014-03-19  浏览次数:55

美国Intrexon

加州圣卡洛斯, 2014年3月13日/美通社-PR Newswire/ -- 合成生物学领导者Intrexon Corporation 今天宣布,该公司收购了Codexis, Inc.(克迪科思公司)旗下位于匈牙利布达佩斯的先进实验室业务。克迪科思是一家致力于为制药和络合物化学行业开发生物催化剂的公司。


此次进行收购将提高Intrexon 的株虫体与蛋白质开发能力,并将加强发酵工艺优化和升级改进。协定达成后,Intrexon 的工业产品部门(IPD) 将接纳布达佩斯实验室中一群富有经验的科学专业人士。布达佩斯团队及其专业知识和Intrexon 一整套合成生物学技术与能力相结合,将能够让Intrexon 更好地为现有合作方提供服务,并在原料药(API) 和工业与消费产品方面吸引新的合作机会。

Intrexon 的工业产品部门致力于为医疗、食品、能源、环境和消费品行业开发生物基解决方案,包括生物生产的原料药,例如新型抗感染药和面向化学品与燃料生产的工程微生物生物催化剂。

Intrexon 工业产品部门总裁罗伯特-沃尔什(Robert F. Walsh) 表示:「向欧洲扩张能够让Intrexon 在与Amneal、强生(Johnson & Johnson) 和Oragenics 等现有合作方合作方面拥有更多灵活性,还能让公司满足国际合作方的需求。我们很高兴让布达佩斯团队加入Intrexon,并期待他们立即做出贡献。」

Intrexon 欧洲与亚洲地区业务开发副总裁Peter Seufer-Wasserthal 博士补充说:「我们所收购的先进工业开发设施与团队能够扩大我们现有工业产品部门的业务,而且它居于布达佩斯的地理位置还能让我们继续发展海外事业,提高我们服务欧洲与亚洲市场的能力。」

讯息来源Intrexon Corporation

Intrexon Acquires Laboratory Operations from Codexis and Expands Presence to Europe
Company Increases Bioproduction Capabilities and Capacity

SAN CARLOS, Calif., March 13, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that it has acquired state-of-the-art laboratory operations in Budapest, Hungary from Codexis, Inc., a developer of biocatalysts for the pharmaceutical and complex chemistry industries.

Intrexon Corporation logo.

The acquisition will expand Intrexon's strain and protein development capabilities, as well as strengthen fermentation process optimization and scale-up.  Through the agreement, Intrexon's Industrial Products Division (IPD) will absorb the Budapest laboratory staff of experienced scientific professionals.  Integration of the Budapest team and their expertise with Intrexon's suite of synthetic biology technologies and capabilities will allowIntrexon to better serve current collaborators and to attract new opportunities for active pharmaceutical ingredients (API) and industrial and consumer product collaborations.

Intrexon's IPD is positioned to develop biologically based solutions across sectors – Health, Food, Energy, Environment, and Consumer – including bioproduction of APIs, for example novel anti-infectives, as well as engineering microbial biocatalysts for chemical and fuel production. 

"The expansion affords Intrexon greater flexibility in existing collaborations including AmnealJohnson & Johnson, and Oragenics and positions the Company to meet demand from international collaborators,"  said  Robert F. Walsh, President of Intrexon's Industrial Products Division.  "We are pleased to integrate the Budapest team into Intrexon and look forward to their immediate contributions."

"The state-of-the-art industrial development facility and team we have acquired not only expands our current IPD operations, but its location inBudapest will enable us to continue growing our interests abroad and strengthen our ability to service the European and Asian markets," added Peter Seufer-Wasserthal, Ph.D., Vice President of Business Development for Europe and Asia.

ab0ut Intrexon Corporation
Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy, Environment, and Consumer markets to create biologically-based products that improve the quality of life and the health of the planet.  Through the company's proprietary UltraVector® platform, Intrexon provides its partners with industrial-scale design and development of complex biological systems.  The UltraVector® platform delivers unprecedented control over the quality, function, and performance of living cells.  We call our synthetic biology approach and integrated technologies Better DNA®, and we invite you to discover more at www.dna.com.

Trademarks
Intrexon, UltraVector, RheoSwitch Therapeutic System, RTS, AttSite, mAbLogix, LEAP, and Better DNA are trademarks of Intrexon and/or its affiliates.  Other names may be trademarks of their respective owners.

Safe Harbor Statement
Some of the statements made in this press release are forward-looking statements.  These forward-looking statements are based upon our current expectations and projections ab0ut future events and generally relate to our plans, objectives and expectations for the development of our business.  Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

For more information contact:

Intrexon Corporation
Marie L. Rossi, Ph.D.
Manager, Technical Communications
Tel:         +1 (301) 556-9944
Email:    PublicRelations@intrexon.com

Photo - http://photos.prnewswire.com/prnh/20130919/NY83283LOGO

SOURCE Intrexon Corporation

 
 
[ 行业资讯搜索 ]  [ 加入收藏 ]  [ 告诉好友 ]  [ 打印本文 ]  [ 关闭窗口 ]

0条 [查看全部]  相关评论

 
推荐行业资讯
点击排行
 
网站首页 | 企业资料认证流程 | 广告服务 | 关于我们 | 联系方式 | 使用协议 | 网站地图 | 排名推广 | 广告服务 | 网站留言 | RSS订阅 | 粤ICP备11050685号-8